Back to Results

10X Genomics Inc (TXG)

Featured in Overvalued Stocks High-Momentum Stocks

10x Genomics, Inc. is a healthcare company focused on life sciences tools and services, with common stock listed on NASDAQ under the ticker TXG. The company develops and sells instruments, consumables, and software used to study biological systems across the United States and international markets including the Americas, Europe, the Middle East and Africa, China, and the Asia Pacific region. Its product portfolio includes the Chromium platform for single-cell analysis, along with related microfluidic chips, consumables, and Chromium instruments. It also provides the Chromium X Series and QuantumScale kits for single-cell RNA and methylation analysis. In spatial biology, the company offers the Visium platform and Visium CytAssist instrument, and it also markets the Xenium Analyzer for in situ RNA detection, together with slides and reagents. Software products include Cell Ranger, Loupe Browser, and Xenium Explorer. 10x Genomics serves academic, government, biopharmaceutical, biotechnology, and other research institutions.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-TXG
$32.26
-29.0% Downside
Overvalued
$39.85
-12.3% Downside
Fair
Great
—
—
—
0.0%
August 6, 2026
-254.3x
7.1x
9.0x
5.487 B
5.303 B
1.5%
90.4%
15.2
—
-539.3%
Send a message
Valuation • Fair Value

10X Genomics Inc (NASDAQ-TXG) Fair Value by Valuation Model

Compare the primary fair value estimate for 10X Genomics Inc (NASDAQ-TXG) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$32.26

Estimated downside of 29.0% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$28.47

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$33.52

Comparable-company valuation reference.

Analyst Price Target

$39.85

Analysts imply downside of 12.3%.

How to read these valuation models

Use this section to compare the primary fair value estimate for 10X Genomics Inc (NASDAQ-TXG) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for 10X Genomics Inc (NASDAQ-TXG)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

638.8 M

Current operating scale indicator.

Revenue Forecast

613.7 M

Forward revenue estimate.

EBITDA

-30.669 M

Current operating profitability reference.

EBITDA Forecast

-77.81 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review 10X Genomics Inc (NASDAQ-TXG) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for 10X Genomics Inc (NASDAQ-TXG)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Great

Positive financial-health read.

Piotroski Score

6

Mid-range quality score.

Beneish M-Score

-2.69

No elevated caution signal from this screen.

Altman Z-Score

15.2

Relatively strong balance-sheet zone.

FCF / Net Income

-539.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for 10X Genomics Inc (NASDAQ-TXG). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for 10X Genomics Inc (NASDAQ-TXG)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 6, 2026

Days to Earnings

16

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for 10X Genomics Inc (NASDAQ-TXG), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

10X Genomics Inc (NASDAQ-TXG) Stock Forecast & Technical Outlook

Review 10X Genomics Inc (NASDAQ-TXG) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for 10X Genomics Inc (NASDAQ-TXG) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for 10X Genomics Inc (NASDAQ-TXG) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for 10X Genomics Inc (NASDAQ-TXG) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for 10X Genomics Inc (NASDAQ-TXG) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for 10X Genomics Inc (NASDAQ-TXG) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for 10X Genomics Inc (NASDAQ-TXG)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, 10X Genomics Inc (NASDAQ-TXG) has a Hold consensus, with 5 buy, 10 hold and 0 sell recommendations in the current data set.

Buy 5
Hold 10
Sell 0
FAQ • Fast Investor Answers

10X Genomics Inc (NASDAQ-TXG) Stock FAQ

Quick answers about 10X Genomics Inc (NASDAQ-TXG) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$32.26
Estimated downside 29.0%
Valuation Rating
Overvalued
Estimated downside of 29.0%
Analyst Target
$39.85
Implied downside 12.3%
Financial Health
Great
Current financial-health read

The current fair value estimate for 10X Genomics Inc (NASDAQ-TXG) is $32.26. This implies an estimated downside of 29.0% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 29.0% versus the current market price.

The available analyst price target for 10X Genomics Inc (NASDAQ-TXG) is $39.85. The analyst target implies estimated downside of 12.3%.

The current financial health read for 10X Genomics Inc (NASDAQ-TXG) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for 10X Genomics Inc (NASDAQ-TXG) is August 6, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for 10X Genomics Inc (NASDAQ-TXG) is -254.3x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for 10X Genomics Inc is 5.487 B.

The current enterprise value listed for 10X Genomics Inc is 5.303 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for 10X Genomics Inc is NASDAQ-TXG, and the stock is listed on NASDAQ.

10X Genomics Inc (NASDAQ-TXG) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for 10X Genomics Inc is 1.5%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for 10X Genomics Inc is 90.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Life Sciences Tools & Services Stocks on NASDAQ View more

Illumina Inc (ILMN) Illumina Inc (ILMN)
Medpace Holdings Inc (MEDP) Medpace Holdings Inc (MEDP)
ICON PLC (ICLR) ICON PLC (ICLR)
Bio-Techne Corp (TECH) Bio-Techne Corp (TECH)
Tempus AI Inc (TEM) Tempus AI Inc (TEM)
Bruker Corporation (BRKR) Bruker Corporation (BRKR)
Repligen Corporation (RGEN) Repligen Corporation (RGEN)
Sotera Health Co (SHC) Sotera Health Co (SHC)
Adaptive Biotechnologies Corp (ADPT) Adaptive Biotechnologies Corp (ADPT)
Maravai Lifesciences Holdings Inc (MRVI) Maravai Lifesciences Holdings Inc (MRVI)
Abcellera Biologics Inc (ABCL) Abcellera Biologics Inc (ABCL)
Fortrea Holdings Inc (FTRE) Fortrea Holdings Inc (FTRE)
BioLife Solutions Inc (BLFS) BioLife Solutions Inc (BLFS)
Personalis Inc (PSNL) Personalis Inc (PSNL)
Azenta Inc (AZTA) Azenta Inc (AZTA)
Cryoport Inc (CYRX) Cryoport Inc (CYRX)
Evotec SE ADR (EVO) Evotec SE ADR (EVO)
Cytek Biosciences Inc (CTKB) Cytek Biosciences Inc (CTKB)
Mesa Laboratories Inc (MLAB) Mesa Laboratories Inc (MLAB)
Pacific Biosciences of California (PACB) Pacific Biosciences of California (PACB)
Standard Biotools Inc (LAB) Standard Biotools Inc (LAB)
OmniAb Inc (OABI) OmniAb Inc (OABI)
Alpha Teknova Inc (TKNO) Alpha Teknova Inc (TKNO)
Nautilus Biotechnology Inc (NAUT) Nautilus Biotechnology Inc (NAUT)